



## ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
[contact@emvision.com.au](mailto:contact@emvision.com.au)

### CORRECTION TO APPENDIX 3Y

EMVision Medical Devices Limited (ASX: EMV) ("**EMVision**" or the "**Company**") lodges the attached correction to the Appendix 3Y Change of Director's Interest Notice for Ron Weinberger released on 7 December 2020. 20,000 indirectly held ordinary shares which were disclosed in the Appendix 3X Initial Director's Interest Notice released on 6 May 2020 were omitted in error.

This announcement was authorised for release by the Company Secretary.

**(ENDS)**

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	EMvision Medical Devices Ltd
<b>ABN</b>	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ronald Weinberger
<b>Date of last notice</b>	6 May 2020

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Deborah Joan Weinberger (spouse)
<b>Date of change</b>	7 December 2020
<b>No. of securities held prior to change</b>	1,000,000 fully paid ordinary shares  1,000,000 unlisted Series A options over ordinary shares, exercise price \$0.35, expiry date 31 December 2021  Deborah Joan Weinberger (spouse) 20,000 fully paid ordinary shares
<b>Class</b>	Unlisted options
<b>Number acquired</b>	1,000,000

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. Refer to 2020 Annual General Meeting Notice of Meeting for estimated valuation details and assumptions.
<b>No. of securities held after change</b>	1,000,000 fully paid ordinary shares  1,000,000 unlisted Series A options over ordinary shares, exercise price \$0.35, expiry date 31 December 2021  1,000,000 unlisted Series G options over ordinary shares, exercise price \$1.25, expiry date 6 May 2023  Deborah Joan Weinberger (spouse) 20,000 fully paid ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.